GlassScriptPhysician profile
Maksim Merenkov
NPI 1407408032
$7,824.11
in general payments reported to CMS, 2019-2025
29 companies · $918 in 2025
The $918 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $790 · 2022: $2,681 · 2023: $1,985 · 2024: $1,451 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,291 · Education: $62.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,291.05 |
| Education | $62.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,383.20 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,001.34 | 2021-2024 | Xarelto |
| Amgen INC. | $917.11 | 2021-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $791.14 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $505.60 | 2021-2025 | Jardiance |
| Pfizer INC. | $430.32 | 2022-2025 | |
| Boston Scientific Corporation | $428.98 | 2022-2025 | Lux-Dx Insertable Cardiac Monitor, Latitude Communicator Power Supply, Varithena Administration Pack |
| Astrazeneca Pharmaceuticals LP | $313.35 | 2021-2025 | Wainua |
| Merck Sharp & Dohme LLC | $304.11 | 2021-2025 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $196.15 | 2021-2023 | Arcalyst |
| Heartflow, INC. | $192.94 | 2022-2024 | Ffrct |
| Lantheus Medical Imaging, INC. | $161.34 | 2021-2024 | Definity |
| Novo Nordisk INC | $151.61 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Alnylam Pharmaceuticals INC. | $149.32 | 2024-2025 | Onpattro |
| Esperion Therapeutics, INC. | $139.01 | 2022-2025 | Nexletol |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $120.03 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $115.20 | 2021-2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $114.08 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $63.86 | 2023-2025 | |
| Amarin Pharma, INC. | $58.98 | 2021-2022 | |
| Harmony Biosciences LLC | $42.49 | 2023 | Wakix |
| Actelion Pharmaceuticals US, INC. | $42.37 | 2025 | Opsumit |
| Regeneron Healthcare Solutions, INC. | $36.70 | 2021 | |
| Abiomed | $31.60 | 2024 | Impella |
| Janssen Scientific Affairs, LLC | $30.65 | 2023 | Xarelto |
| Edwards Lifesciences Corporation | $29.50 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.79 | 2023 | |
| Axsome Therapeutics, INC. | $25.61 | 2023 | Sunosi |
| Astellas Pharma US INC | $21.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maksim Merenkov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.